# Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery

> **NCT02319629** · NA · UNKNOWN · sponsor: **HaEmek Medical Center, Israel** · enrollment: 266 (estimated)

## Conditions studied

- Morbid Obesity

## Interventions

- **DRUG:** URSODIOL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02319629
- **Lead sponsor:** HaEmek Medical Center, Israel
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 266 (ESTIMATED)
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319629, "Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02319629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*